Skip to main content
Fig. 2 | Breast Cancer Research

Fig. 2

From: Elacestrant (RAD1901) exhibits anti-tumor activity in multiple ER+ breast cancer models resistant to CDK4/6 inhibitors

Fig. 2

CDK4/6i-resistant cell lines retain ER and ER signaling. a Western blot analysis of ER and downstream ER target genes (GREB1/PR) in the CDK4/6i-sensitive and CDK4/6i-resistant ESR1 wild-type and ESR1 mutant cell lines. PalboS/PalboR, RiboS/RiboR, and AbemaS/AbemaR cells were treated with either control or the indicated CDK4/6i for 24 h. b Table summarizing the changes in ER and ER target genes in the resistant cells when compared to the sensitive cell lines

Back to article page